Ritual and Religious Use

The clearest continuous tradition is South Asian. Cannabis appears in the Vedic literature, and preparations — bhang, ganja and charas, distinguished by which part of the plant is used — are integrated into Hindu religious practice, particularly in association with Shiva. Bhang remains part of festival observance, notably Holi and Maha Shivaratri, and occupies a legally distinct position in India from other cannabis preparations.

Elsewhere, evidence is more fragmentary but real. Herodotus described Scythian funerary rites involving cannabis smoke in the fifth century BCE. Archaeological work at burial sites in Central Asia has found residue consistent with cannabis burned in ritual contexts. Traces have been identified at sites in the ancient Near East.

Rastafari, emerging in twentieth-century Jamaica, incorporated cannabis as a sacrament, and that association carried into global popular culture through reggae — one of the more direct routes by which a religious practice became a mainstream cultural symbol.

The longer agricultural and medical history is in the history of cannabis around the world.

Cannabis as Political Symbol

Cannabis acquired its modern political meaning in the twentieth century, and largely through prohibition rather than despite it.

Criminalisation made use an act of nonconformity, and the 1960s counterculture adopted it accordingly. From that point, cannabis carried meaning far beyond its effects — a marker of generational and political identity rather than a substance.

Enforcement gave that symbolism a much harder edge. Prohibition was not enforced evenly, and the resulting criminal records fell disproportionately on particular communities. That history is why cannabis reform is bound up with criminal justice and equity questions in a way that reform of other regulated products is not. See diversity, equity and inclusion in the cannabis industry and the regulatory history.

The Creativity Question

The association between cannabis and creative work is old and heavily documented in the accounts of musicians, writers and artists. Whether it holds up under examination is a separate question.

Research findings are mixed and, where they are clearer, less flattering than the folklore.

Studies examining divergent thinking — generating multiple solutions to open-ended problems — have found modest effects at low doses in some participants, with performance declining at higher doses. Convergent thinking, the ability to identify a single correct answer, generally does not improve and often worsens.

Several studies have found a consistent gap between perceived and measured creativity: participants under the influence rated their own ideas as more creative than independent judges did. That finding recurs often enough to be worth taking seriously.

A reasonable reading: cannabis may loosen associative thinking in ways that some people find useful during idea generation, and it does not appear to improve the evaluation and execution that turn ideas into work. The historical association may also reflect selection — creative fields have long been more permissive about substances generally — rather than causation.

Cannabis Tourism

Legalization created a travel category. Amsterdam’s coffee shops were the original example, drawing visitors for decades under a tolerance policy rather than formal legalization. Legal markets in North America have since developed their own versions.

What it looks like in practice: dispensary visits and product tourism, cultivation and production facility tours, cannabis-friendly accommodation, and event tourism around cannabis-focused festivals and competitions.

The economics are real but smaller than early projections suggested, and the sector faces persistent friction. Consumption is generally prohibited in public and in most hotels, so visitors buy legally and then have nowhere lawful to consume. Federal restrictions block transport across state and national borders. And some destinations have found the reputational trade-off unwelcome, with Amsterdam actively discouraging the visitor segment it became known for.

The Language Problem

Terminology in cannabis carries history worth being aware of.

“Marijuana” entered American usage in the early twentieth century and was promoted in prohibition-era campaigning partly because its foreignness served a purpose — the plant was already familiar to physicians and pharmacists as cannabis. Some in the industry prefer “cannabis” for that reason. Others regard the objection as overstated, and “marijuana” remains in wide legal and everyday use, including in Missouri’s own statutory language.

Both terms appear throughout this site, because both are what people actually search for and use.

Culture Meeting Regulation

The cultural dimension is not separable from the regulatory one, which is a point worth making in a testing context.

Cannabis was prohibited partly for cultural and racial reasons rather than evidentiary ones, and that prohibition prevented the research and standardization that would ordinarily accompany a medicine or consumer product. Legal markets are now building — in the space of a few years — the measurement infrastructure that other regulated products developed over a century.

That is the practical legacy of the cultural history. The reason cannabis testing is a young discipline with unresolved standardization problems is not scientific difficulty. It is that the science was not allowed to happen. See the science behind medical cannabis research and standardization and transparent reporting.

The post Cannabis in Culture, Ritual and Creativity appeared first on TruMo Analytics.

What Is in Hemp Seed

Protein. Hemp seed contains roughly 25–30% protein by weight, and it is a complete protein — containing all nine essential amino acids. The main storage proteins, edestin and albumin, are readily digestible. That combination is uncommon in plant sources and is the basis of most of hemp’s nutritional interest.

Fatty acids. Hemp seed is around 30% oil, and the fatty acid profile is the more distinctive part. The omega-6 to omega-3 ratio is roughly 3:1, close to what is generally regarded as favorable — most Western diets run far higher in omega-6. Hemp oil also contains gamma-linolenic acid (GLA), which is present in few common foods.

Fiber. Whole hemp seeds contain useful quantities of both soluble and insoluble fiber. Hulled hemp hearts, which is what most people buy, contain considerably less because the fiber is largely in the hull.

Micronutrients. Vitamin E, magnesium, phosphorus, potassium, iron and zinc, in meaningful amounts.

The Forms It Comes In

Hemp hearts — hulled seeds. Soft, mildly nutty, eaten raw on food or blended. The most common retail form.

Whole seeds — with hull intact. Higher fiber, harder texture.

Hemp seed oil — cold-pressed. Best used unheated, as a finishing oil or in dressings, since the polyunsaturated fatty acids that make it nutritionally interesting are also what makes it unsuitable for high-heat cooking. It oxidises readily, so it should be kept cool and dark and used within a reasonable period.

Hemp protein powder — the meal left after oil extraction, milled. Lower protein concentration than isolated soy or whey powders, with fiber and micronutrients retained.

Hemp milk — blended seed and water.

An Important Distinction

Hemp seed oil and CBD oil are different products, and the conflation is widespread enough to be a real consumer problem.

Hemp seed oil is pressed from seeds. It contains essentially no cannabinoids, because cannabinoids are produced in the trichomes on flowers and leaves, not in seeds. It is a food oil.

CBD oil is extracted from flower and leaf material and is a cannabinoid product.

Products are sometimes marketed in ways that blur this — “hemp oil” on a label can mean either, and some products priced as CBD contain only seed oil. Checking the certificate of analysis resolves it in seconds: seed oil shows no meaningful cannabinoid content.

What the Nutritional Evidence Supports

Hemp seed’s composition is well documented. What that composition does clinically is a narrower claim.

The reasonable statements are compositional: hemp seed is a complete plant protein, it has a favorable omega-6 to omega-3 ratio relative to typical Western intake, and it contains GLA, which few foods do.

Claims that hemp seed treats or prevents specific conditions go beyond what has been demonstrated. Most human research on hemp seed is limited, and the general benefits attributed to it are usually extrapolated from what is known about the individual nutrients rather than from trials of hemp seed itself.

It is a nutritious food. That is a sufficient claim, and it is defensible.

Practical Notes

Hemp seed is high in fat and therefore calorie-dense — a useful thing to know when adding it to a diet rather than substituting it in.

Fiber content differs sharply between whole seeds and hulled hearts, so introducing whole seeds abruptly can cause digestive discomfort.

Both seed and oil oxidise. Refrigeration after opening extends usable life considerably, and rancid hemp oil is unpleasant enough to be obvious.

Trace THC is present in some hemp seed products through contact between seeds and plant material during harvest. Levels are very low and well below what would cause effects, though people subject to drug testing occasionally raise it as a concern. Well-processed products minimize it.

Testing Food-Grade Hemp

This is the part that gets skipped, and it matters more for hemp than for most foods.

Heavy metals. Hemp is an efficient bioaccumulator — it draws elements out of soil and water and concentrates them in tissue, which is why it is used deliberately for soil remediation. Food-grade hemp needs heavy metal screening, particularly where the growing site has any industrial or intensive agricultural history.

Pesticides. Hemp entering the food chain faces food-safety residue limits, and the approved product list for hemp is narrow.

Microbials and mycotoxins. Standard food-safety requirements. Seed stored at inadequate moisture levels can develop mold, and mycotoxins persist after the mold is gone.

THC compliance. Confirming the material derives from compliant hemp.

The gap here is regulatory rather than technical. Hemp food products sit outside the mandatory batch-testing regime that governs dispensary cannabis, which means testing depends on the manufacturer choosing to do it. Reputable producers publish full panels. Others publish nothing, and the packaging looks identical.

The check is the same as for any cannabis product: find the certificate of analysis, match the batch, confirm contaminants were tested and not just composition. See how third-party testing protects consumers.

Hemp’s other agricultural and industrial applications are covered in hemp on the farm and industrial hemp uses.

The post Hemp as Food: Seeds, Oil and Nutrition appeared first on TruMo Analytics.

Both halves of that belong in any honest discussion of cannabis and pets.

THC Is Genuinely Dangerous for Dogs

This needs stating before anything else, because it is the part with immediate consequences.

Dogs have a considerably higher density of CB1 receptors in the brain than humans, particularly in the cerebellum and brainstem. That physiological difference means THC affects them more severely and at lower doses relative to body weight.

Signs of cannabis toxicity in dogs include loss of coordination, disorientation, dilated pupils, excessive drooling, vomiting, urinary incontinence, tremors, unusual sensitivity to sound and touch, and in severe cases, low heart rate, low body temperature, seizures and coma.

Cannabis toxicity in dogs is very rarely fatal on its own, but severe cases require veterinary intervention, and edibles carry compounding risks — chocolate is separately toxic to dogs, xylitol far more so, and a chocolate edible presents all three hazards simultaneously.

If a dog has ingested cannabis, contact a vet. Bring the packaging if you have it. Be straightforward about what and how much — veterinary staff need the information to treat, not to judge, and withholding it delays care.

The same applies to cats, though ingestion is less common.

Storage is the whole prevention story: sealed, secured, out of reach. The general storage guidance in how to store cannabis properly applies, with the addition that “out of reach” means genuinely out of reach of an animal that can jump onto a worktop.

What CBD Research in Animals Actually Shows

CBD is not intoxicating and has a different profile. The veterinary evidence base is small but no longer non-existent.

Osteoarthritis in dogs is the most studied application. Several controlled studies have reported improvements in comfort and activity in dogs with osteoarthritis receiving CBD. These are small studies, and the results are consistent enough to be of genuine interest. This is the strongest evidence in the field.

Seizures in dogs. A small controlled study reported a reduction in seizure frequency in dogs with idiopathic epilepsy receiving CBD alongside conventional medication, though the proportion of dogs classified as responders was not markedly different from control. Promising, not established.

Anxiety. Widely marketed and thinly evidenced. Studies in dogs have produced mixed results, with several finding no significant effect on situational anxiety measures. This is the largest gap between marketing and evidence in the category.

Pharmacokinetics. Reasonably characterized in dogs — how CBD is absorbed, metabolised and eliminated is better understood than what it does.

Research in cats is considerably thinner, and cats appear to metabolise cannabinoids differently from dogs. Extrapolating dog findings to cats is not sound.

What Is Known About Safety

Studies in dogs have generally found CBD reasonably tolerated at the doses studied, with the most consistent finding being elevated liver enzymes — alkaline phosphatase in particular.

Whether that indicates clinically meaningful liver stress over long-term use is not established, and it is the main reason veterinary monitoring matters for any animal on CBD for an extended period. Blood work before starting and periodically afterwards is a reasonable precaution.

Drug interactions are a real consideration. Cannabinoids affect the same metabolic enzymes that process many veterinary medications, which can alter their levels. The mechanism is the same one described in cannabis and drug interactions.

The Product Quality Problem

This is where testing becomes central, and where the pet market is worse than the human one.

Analyses of retail pet CBD products have repeatedly found CBD content that does not match the label — sometimes far below, sometimes above, sometimes absent entirely. Some products have been found to contain THC in a category where THC is specifically the compound to avoid.

Pet products sit outside the mandatory batch-testing regime that governs dispensary cannabis. Testing is voluntary, and nothing on the packaging distinguishes a manufacturer that tests thoroughly from one that does not.

For an animal that cannot report how it feels and weighs a fraction of an adult human, an inaccurate dose matters more, not less.

What to check

1. A current certificate of analysis, with a batch number matching the product.
2. CBD content verified against the label claim.
3. THC content, which for a pet product should be as close to zero as the analysis can establish.
4. Contaminant panels — pesticides, heavy metals, residual solvents, microbials. Hemp is an efficient bioaccumulator, which makes heavy metal screening particularly relevant.
5. An accredited third-party laboratory, named on the report.

How to read the report is covered in reading lab results, and why independence matters in third-party testing.

A Reasonable Position

CBD for osteoarthritis in dogs has the beginnings of a real evidence base and is worth discussing with a veterinarian. Most other applications are marketed well ahead of what has been demonstrated.

THC is not appropriate for animals and is a veterinary emergency in meaningful quantities.

And whatever the application, the product needs to be verified — because in a market with no mandatory testing, the label is a claim rather than information.

The post Cannabis and Pets: What the Evidence Actually Shows appeared first on TruMo Analytics.

Some of what is claimed for cannabis skincare is reasonable. Some of it is not, and a fair amount of it involves an ingredient that is not what the label suggests.

Two Very Different Ingredients

This distinction accounts for most of the confusion in the category.

Hemp seed oil is pressed from seeds and contains essentially no cannabinoids. It is a conventional cosmetic oil: rich in linoleic and alpha-linolenic acids, light in texture, non-comedogenic, and a perfectly good emollient. It has been used in cosmetics for a long time and its properties are uncontroversial.

CBD and other cannabinoid extracts come from flower and leaf material. These are the active ingredients that the marketing is usually about, and they cost considerably more.

Products routinely blur the two. “Hemp oil” on an ingredient list can mean either. A product marketed on cannabinoid benefits that lists only Cannabis sativa seed oil contains no meaningful cannabinoids — it is a seed-oil moisturiser priced as something else.

The check takes seconds: the certificate of analysis shows cannabinoid content, or shows none.

What Topicals Actually Do

Cannabinoid receptors are present in skin, and the skin has its own endocannabinoid signalling involved in barrier function, sebum production and inflammatory response. That is a real physiological basis, and it is where the interest comes from. See the endocannabinoid system.

What follows from it is narrower than the marketing suggests.

Topical cannabinoids act locally. Cannabinoids are lipophilic and do not readily cross into systemic circulation through intact skin. That is why topicals — including THC-containing ones — do not produce intoxication. It also means the effect is confined to where the product is applied.

Penetration depth is limited. Reaching deeper tissue requires formulation work — carriers, penetration enhancers, liposomal delivery. A cannabinoid suspended in a basic cream stays largely at the surface.

Concentration is frequently too low to matter. Many products contain cannabinoid quantities that would be unlikely to produce a measurable effect even with good delivery. The ingredient is present for the label.

Where the Evidence Sits

Emollient and barrier effects from hemp seed oil are straightforward and not really disputed. It is a good cosmetic oil.

Anti-inflammatory activity of cannabinoids in skin has preclinical support and limited clinical evidence. Small studies have looked at CBD in inflammatory skin conditions with some encouraging results, and the work is early.

Acne — preclinical work suggests CBD may affect sebum production, and human evidence is minimal.

Localised pain and soreness is the most commonly marketed use for topicals. Evidence is limited and complicated by the fact that many such products also contain menthol, camphor or capsaicin, which produce noticeable sensory effects independent of any cannabinoid.

Anti-aging claims are largely extrapolation from antioxidant activity measured in laboratory conditions, which is a very long way from a clinical outcome.

The general pattern matches the rest of the field: plausible mechanism, thin clinical evidence, confident marketing. See the science behind medical cannabis research.

The Regulatory Position

Cosmetics are regulated more lightly than food or drugs, which is a large part of why the category grew so fast.

The line that matters is between a cosmetic claim and a drug claim. Saying a product moisturises skin is a cosmetic claim. Saying it treats eczema, relieves arthritis pain or reduces inflammation positions it as a drug — which triggers a different regulatory framework and is where enforcement has concentrated.

Products sold through licensed dispensaries fall under cannabis regulation and carry the associated testing requirements. Products sold as hemp-derived cosmetics outside that system generally do not, which produces the same oversight gap seen across hemp retail.

Testing Cannabis Cosmetics

Topicals are applied to skin, often daily, sometimes to broken or irritated skin. That is a reason for more scrutiny, not less.

Potency. Verifying that stated cannabinoid content is accurate. Independent analyses of retail CBD cosmetics have repeatedly found content well off the label claim.

Heavy metals. Hemp is an efficient bioaccumulator, which makes heavy metal screening relevant for any hemp-derived ingredient. See cannabis as a phytoremediation crop.

Pesticides. Residues concentrate through extraction alongside cannabinoids.

Residual solvents. Where the extract was solvent-produced.

Microbials. Cosmetics are a microbial risk category in their own right — water-containing formulations support growth, and preservative systems have to be adequate.

THC content. For hemp-derived products, confirming compliance with the applicable threshold.

We test topicals as part of the extracts and topicals category. Panel detail is in contaminant testing explained.

Buying Sensibly

• Check which ingredient it actually contains. Seed oil and cannabinoid extract are different products at different prices.
• Look for a stated cannabinoid concentration, not just “contains CBD”.
• Ask for the certificate of analysis and match the batch.
• Discount therapeutic claims. A cosmetic making drug claims is telling you something about the manufacturer.
• Read the full ingredient list. If it contains menthol or capsaicin, that is where the sensation is coming from.

Hemp seed oil is a good cosmetic ingredient with no need for a cannabis story attached. Cannabinoid topicals are more interesting and less proven. Both are worth buying on the basis of what the analysis shows rather than what the packaging says.

The post Cannabis in Beauty and Personal Care appeared first on TruMo Analytics.

A more useful approach is to look at the forces actually operating, and be explicit about which are predictable and which are not.

What Is Reasonably Predictable

Consolidation continues

Every legalized market has followed the same arc: fragmentation into many small operators, then consolidation as price competition and compliance costs favor scale.

The drivers are consistent — capital requirements rising as compliance tightens, price compression eliminating thin margins, and multi-state operators preferring fewer, larger partners. Missouri is a clear example: with license numbers capped in the state constitution, the pressure shows up as consolidation instead, and a single operator has been tied to more than a quarter of the state’s dispensary licenses.

Price keeps falling

Legal cannabis prices have declined in essentially every mature market, often below illicit prices. Production efficiency improves, supply outpaces demand, and competition intensifies.

This is good for consumers and difficult for producers. It is also the mechanism forcing consolidation, and there is no evident floor beyond production cost.

Regulation tightens

No jurisdiction has meaningfully loosened its testing, labeling or packaging requirements after implementation. The direction is consistently toward more specific analyte lists, stricter laboratory accreditation, and more enforcement capability. See the future of cannabis lab testing.

Quality becomes the differentiator

Once price competition exhausts itself, differentiation moves to what can actually be demonstrated: consistency between batches, verified contaminant profiles, terpene data buyers can use. That favours operators with real process control and documented results, and it is the point at which testing shifts from cost to asset.

What Is Genuinely Uncertain

Federal reform in the United States

The single largest variable, and the one most confidently predicted by people with no basis for confidence.

Rescheduling or descheduling would change taxation — the current treatment under Section 280E prevents ordinary business deductions and is a substantial burden — banking access, research capability, and eventually interstate commerce.

Interstate commerce would be the most transformative piece. It would allow production to concentrate where it is cheapest, which would be difficult for high-cost states and advantageous for low-cost producers with surplus capacity. A capped market like Missouri’s sits awkwardly here: license scarcity supports in-state value today, and interstate commerce would erode exactly that.

Timing is unpredictable. Anyone giving you a date is guessing.

How much illicit supply persists

Legal markets have not displaced illicit ones as completely as expected. Where taxes are high and licensed retail is thin, illicit supply remains competitive.

This matters beyond revenue. Illicit product is untested product, and every consumer buying outside the regulated system is outside the safety framework the system exists to provide. See the risks of untested cannabis products.

Hemp-derived intoxicants

The 2018 Farm Bill’s hemp definition created an unintended market in intoxicating cannabinoids derived from hemp — delta-8 and a growing list of others — sold outside the cannabis regulatory system, frequently without meaningful testing.

How this is resolved is unresolved. Closing the gap would remove a significant unregulated market; leaving it open sustains a parallel channel with no safety framework. Either outcome materially affects the regulated sector.

Where Products Are Going

Several directions look durable.

Beyond THC percentage. The market’s fixation on potency is finally weakening as consumers find that higher numbers do not deliver what they expected. Full chemotype information — cannabinoid and terpene profiles — is a better basis for differentiation, and it depends on terpene analysis being run and published.

Minor cannabinoids. CBG, CBN and others, driven by interest in profiles beyond the two everyone knows. Testing panels are broadening accordingly.

Beverages. Growing, and the most analytically demanding format — emulsion stability, cannabinoid adsorption onto containers, and homogeneity all make them harder to get right. See why edibles are tested differently.

Precision dosing. Low-dose, consistently dosed products for consumers who want a predictable effect rather than a strong one. This depends entirely on manufacturing consistency and accurate potency measurement.

What Would Genuinely Change Things

Two developments would reshape the sector more than any product trend.

A national standard. Whether through federal reform or voluntary convergence, harmonised testing methods and limits would make results comparable across markets, remove duplicated compliance work, and eliminate most of the lab-shopping incentive. See standardization and transparent reporting.

A stronger clinical evidence base. Cannabis’s medical positioning currently rests on evidence that is solid for a few indications and thin for most. Better research would clarify where the genuine applications are — and would also close off some of the claims currently made. See the science behind medical cannabis research.

What Operators Should Actually Plan For

• Assume prices stay low. Build a cost structure that works at current or lower prices rather than one that requires a recovery.
• Assume regulation tightens. Building above the current minimum is cheaper than retrofitting.
• Invest in consistency. It is what quality competition is actually measured on, and it shows up in test data before it shows up in reputation.
• Do not plan around federal reform. Be positioned to benefit if it arrives; do not depend on it.
• Treat testing as information. Operators who use their data to improve process get compounding returns from spend they are making anyway. See what cannabis lab testing is.

The industry’s next phase looks less like a gold rush and more like an ordinary regulated agricultural and manufacturing sector — thinner margins, higher standards, and competition on execution. That is a less exciting story and a more durable one.

The post The Future of the Cannabis Industry appeared first on TruMo Analytics.

The Underlying Problem

Cannabis use rates across racial groups in the United States have been broadly similar, while arrest rates have not. Black Americans have been arrested for cannabis offences at several times the rate of white Americans over decades of enforcement.

A cannabis conviction carries consequences well beyond any sentence: barriers to employment, housing, education funding, professional licensing and, in some cases, immigration status. Those effects compound across a lifetime and across families.

When legalization arrived, it created a licensed industry — and the people best positioned to enter it were those with capital, clean records and access to real estate and legal advice. Which is broadly not the population that carried the enforcement burden.

Where Ownership Actually Sits

Surveys of the industry have consistently found that ownership of cannabis businesses skews heavily white, and that the gap is widest at the levels where capital requirements are highest — cultivation and manufacturing rather than retail.

Several mechanisms sustain it.

Capital. Cannabis businesses cannot access conventional bank lending, because federal illegality keeps most institutions out. Entry therefore depends on private capital, which flows through existing networks. See why dispensaries still operate in cash.

Licensing costs. Application fees, legal work, compliance build-out and real estate secured before revenue exists. In capped-license states the total can run into the hundreds of thousands.

Criminal record exclusions. Many states barred people with drug convictions from holding licenses — excluding, by design, those most affected by the prohibition being unwound. Several states have narrowed these provisions since.

Real estate. Zoning restrictions limit where cannabis businesses can operate, and compliant property is scarce and expensive. Landlords also decline cannabis tenants.

Tax treatment. Section 280E prevents cannabis businesses deducting ordinary expenses, which means effective tax rates far above other industries. Undercapitalised operators feel that most.

What Social Equity Programs Tried

Many states and cities built social equity provisions into their frameworks, typically combining license priority or set-asides for applicants from disproportionately affected areas or with prior convictions, fee reductions or waivers, technical assistance and business training, and in some cases grant or loan funds.

Why Most Underdelivered

Assessments have been broadly critical, for reasons that recur across jurisdictions.

A license is not a business. Priority access does not supply the capital needed to build out a facility, secure property and operate until revenue arrives. Equity licensees have frequently held a license they could not use.

Predatory partnerships. Undercapitalised licensees sought investors, and some arrangements left the equity holder with a nominal stake and little control — satisfying the program on paper while transferring the value.

Delays. Slow implementation meant established operators were trading and building market position before equity licensees opened. In a consolidating market, that head start is decisive.

Litigation. Equity provisions have been challenged in court, and some have been struck down or suspended, leaving applicants stranded mid-process.

Eligibility mismatches. Criteria based on residence in designated areas sometimes admitted people unaffected by enforcement while excluding people who were.

What Has Worked Better

A few approaches have shown more effect.

Automatic expungement. States that expunged prior cannabis convictions automatically, rather than requiring individual petitions, cleared far more records. Petition-based processes reach a small fraction of those eligible because they require awareness, time and usually legal help.

Direct capital. Grant and low-interest loan programs, funded from cannabis tax revenue, address the actual binding constraint rather than the license.

Anti-predatory ownership rules. Requirements around control, profit share and transfer restrictions make nominal-ownership arrangements harder.

Revenue reinvestment. Directing a share of cannabis tax revenue to communities affected by enforcement — for services rather than only for industry entry.

Beyond Ownership

Employment diversity in cannabis is generally better than ownership diversity, though it thins toward senior roles. The pattern is familiar from other industries: representation at entry level, less in management, least at executive and board level.

Cannabis has some advantages here — it is a young industry without decades of entrenched hiring practice, and many roles have no formal credential requirement, which lowers barriers. What it lacks is the established pipeline and development infrastructure that older sectors have built. See careers in the cannabis industry.

Where This Sits for a Laboratory

Testing laboratories are not licensing authorities and cannot fix structural equity problems in the sector. What we can be clear about is that the standard applied to a sample does not vary with who submitted it.

That matters more than it sounds. A small operator without in-house compliance expertise depends more on a laboratory that will explain a result and help identify a cause than a large one with a technical team does. A laboratory that only engages properly with high-volume clients quietly widens the gap. The service expectation is set out in how to choose a cannabis testing laboratory.

An Honest Assessment

The cannabis industry has not resolved this. Ownership remains concentrated, most equity programs have delivered less than intended, and consolidation is making entry harder rather than easier.

Where progress has been real, it has come from addressing the binding constraint — capital, records, control — rather than from license priority alone. That is a narrower conclusion than the sector’s rhetoric, and it is the one the evidence supports. Related ground in the ethics of cannabis.

The post Diversity, Equity and Inclusion in the Cannabis Industry appeared first on TruMo Analytics.

Origins in Central Asia

Cannabis appears to have originated in Central Asia, with archaeological and genetic evidence pointing to the region around modern-day Mongolia and southern Siberia. Hemp fiber imprints on pottery from what is now China date back several thousand years, making it among the oldest documented fiber crops.

Early use was practical: fiber for rope, textiles and paper, and seeds for food and oil. Hemp seed was a staple grain in parts of ancient China before being displaced by higher-yielding cereals.

Medicine in China and India

Chinese medical texts record cannabis preparations from antiquity, attributed to the legendary figure Shen Nung and compiled over centuries into the pharmacopoeial tradition. Recorded applications included pain, digestive complaints, and conditions we would now describe differently.

In India the plant took on a different character. Cannabis appears in the Vedic tradition, and preparations — bhang, ganja and charas, distinguished by which part of the plant was used and how — were incorporated into both medical practice and religious observance. Ayurvedic medicine records a range of applications, and the association with Shiva placed cannabis inside religious life rather than alongside it.

That integration is the reason cannabis use in South Asia has a continuity that Western use does not. It was never entirely separated from ritual and medicine into a purely recreational category. More on that in cannabis in culture, ritual and creativity.

Westward Through the Middle East

Cannabis spread west through Persia and the Arab world, where it appears in medical texts as a treatment for pain, inflammation and epilepsy. Islamic scholars documented its properties in detail, and it was through Arabic medical literature that a good deal of this knowledge later reached Europe.

Herodotus described Scythian funerary practices involving cannabis smoke as early as the fifth century BCE — one of the oldest surviving accounts of inhalation for effect rather than for fiber or food.

Hemp in Europe and the Americas

In Europe, cannabis was grown overwhelmingly as hemp. Its fiber was the material of maritime power — rope, rigging, sailcloth — and its cultivation was in places compulsory. Several European states required landowners to grow hemp because naval capacity depended on it.

Colonists brought hemp to North America for the same reason. It was a required crop in parts of colonial America, and it remained an ordinary agricultural commodity into the twentieth century. The psychoactive properties of the plant were largely irrelevant to its cultivation in this context: fiber varieties were selected for stalk quality, not for resin.

Into Western Medicine

Cannabis entered Western medical practice substantially through William Brooke O’Shaughnessy, an Irish physician working in Calcutta in the 1830s. He studied Indian medical use, conducted his own trials, and published findings covering rheumatism, tetanus, cholera and convulsions — including a widely noted case of infantile convulsions.

His work brought cannabis into British and then American pharmacies. By the late nineteenth century it was a standard preparation, listed in the United States Pharmacopeia and sold by major manufacturers as tinctures and extracts.

Its medical decline began before any legal restriction. Injectable opiates and later aspirin offered more predictable dosing — cannabis preparations varied enormously in strength, which is the same problem potency testing exists to solve today.

Prohibition

The twentieth century reversed everything. International drug control treaties, national prohibitions, and in the United States the 1937 Marihuana Tax Act removed cannabis from ordinary commerce and then from medicine. It was dropped from the United States Pharmacopeia in 1942 and placed in Schedule I of the Controlled Substances Act in 1970.

The full account of that reversal, including the legislative history, is in from the Marihuana Tax Act to Amendment 3.

Prohibition did not end cultivation. It moved it — into clandestine production, selected increasingly for potency and concealability rather than for fiber or seed. Much of what defines modern cannabis genetics is downstream of decisions made by growers operating illegally. See cannabis genetics.

The Modern Reversal

Reform began at the margins. California’s medical program in 1996 was the first modern breach in the United States. Uruguay legalized adult use nationally in 2013, Canada in 2018, and a majority of US states now permit medical or adult use in some form.

Hemp separated back out along the way. The 2018 Farm Bill removed cannabis containing no more than 0.3% delta-9 THC from federal control, restoring — in legal terms — the distinction between fiber and drug crops that had existed agriculturally for most of the plant’s history.

The global picture is set out in where cannabis is legal around the world.

What the History Actually Shows

Two things worth taking from five thousand years.

The prohibition era was an interruption, not the norm. Cannabis was an ordinary crop and an ordinary medicine for most of recorded history, and the twentieth century was the exception.

And the recurring practical problem has always been the same. Preparations varied unpredictably in strength, which limited their medical usefulness in the nineteenth century exactly as it would today. What has changed is not the plant — it is that we can now measure what is in it. That capability is the actual dividing line between historical use and modern regulated use, and it is what cannabis lab testing provides.

The post The History of Cannabis Around the World appeared first on TruMo Analytics.

Measured against that standard, the record is uneven. These are the questions the industry has not resolved.

The Legacy of Enforcement

The industry exists because a prohibition ended. That prohibition was enforced unevenly, and people are still carrying its consequences while a legal industry profits from the same activity.

The concrete questions are whether prior convictions are being expunged, whether people with those convictions can participate in the legal industry, and whether tax revenue reaches the communities where enforcement concentrated.

Progress has been real and partial. Automatic expungement in states that adopted it has cleared far more records than petition-based processes. Most social equity licensing programs have underdelivered, largely because a license does not solve a capital problem. Detail in diversity, equity and inclusion in the cannabis industry.

Labour

Cannabis employs a substantial number of people in cultivation, trimming, processing and retail, and working conditions vary widely.

Trimming in particular has a history of piece-rate work, seasonal insecurity and — in the transition from illicit to legal production — practices that would not survive scrutiny in other agriculture. The legal sector has improved on this by virtue of being visible, and unionisation has advanced in several markets.

Occupational safety is a genuine issue. Extraction work involves flammable solvents under pressure. Cultivation and drying spaces carry mold exposure risk — which is a worker health question as much as a product quality one, as noted in storage and ventilation. Some workers have developed occupational sensitisation to cannabis dust and pollen.

Environmental Footprint

Indoor cannabis production is among the most energy-intensive forms of agriculture, and the industry has been slow to confront this because indoor product commands a price premium.

Water use in drought-prone regions, packaging waste driven by child-resistance requirements, peat-based growing media, and disposal rules that require mixing waste with other material all add to it. Each is covered in sustainability in cannabis cultivation and cannabis waste disposal.

The uncomfortable part is that the lowest-footprint production method — outdoor — is the one the market values least. That is a consumer preference problem as much as an industry one, and it will not resolve through operator goodwill alone.

Marketing and Health Claims

This is where the gap between rhetoric and evidence is widest.

Cannabis is routinely marketed with therapeutic claims that the research does not support. Products are promoted for anxiety, sleep, pain and inflammation on evidence that is preliminary at best, and the confident version reaching consumers runs well ahead of what has been demonstrated. See the science behind medical cannabis research.

The potency arms race is a second problem. Marketing built around THC percentage encourages consumers toward higher-potency products without evidence that higher potency serves them better, and it creates the commercial pressure behind the integrity problems described in lab ethics and data integrity.

And risks are systematically under-communicated. Cannabis use disorder, the association between high-potency use and psychosis risk, cannabinoid hyperemesis syndrome, and interactions with other medications are all documented, and rarely appear in marketing.

Vulnerable Populations

Some groups warrant more care than the industry generally exercises.

Adolescents, where evidence on developing brains is a live concern and where product design and marketing that appeals to young people is a legitimate objection. Pregnant and breastfeeding people, where evidence is limited and caution is warranted. People with psychiatric history, where the psychosis association is strongest. Older adults on multiple medications, where interactions matter more — see cannabis and drug interactions.

Testing and Independence

Within testing specifically, the ethical questions are narrow and consequential.

Producers select and pay the laboratories that assess them, which creates pressure toward accommodating results. Laboratories hold commercially sensitive client data. And the incentive to compete on outcome rather than capability is always present.

The countermeasures are known: accreditation, independent sampling, blind proficiency testing, data integrity controls, and enforcement that is published rather than private. All of it is covered in lab ethics and data integrity.

The reason a laboratory should be willing to state this plainly is that a testing function whose independence is assumed rather than demonstrated is not performing the role it claims.

What Would Constitute Progress

Concrete rather than aspirational:

• Automatic expungement rather than petition-based processes
• Capital access for equity licensees, not license priority alone
• Marketing claims constrained to what evidence supports
• Risks communicated alongside benefits, as a norm rather than a legal minimum
• Environmental reporting that allows comparison between operators
• Occupational safety treated as seriously as product safety
• Testing independence protected structurally, not left to goodwill

Cannabis has an opportunity most industries do not — it is young enough to establish norms rather than inherit them. Whether it uses that opportunity is still open. The commercial pressures shaping the answer are in the future of the cannabis industry.

The post The Ethics of Cannabis: Social and Environmental Concerns appeared first on TruMo Analytics.

What Phytoremediation Is

Phytoremediation is the use of plants to remove, stabilise or break down contaminants in soil, water or air. It works through several mechanisms.

Phytoextraction — the plant takes contaminants up through its roots and concentrates them in its tissue. The plant is then harvested and disposed of, removing the contaminant from the site.

Phytostabilisation — roots bind contaminants in place, preventing them leaching into groundwater or blowing away as dust.

Rhizodegradation — microbial communities around the roots break organic contaminants down.

Phytovolatilisation — the plant takes up a contaminant and releases it, or a modified form of it, through its leaves.

Cannabis participates in all four, and it is unusually good at the first.

Why Hemp Is Well Suited to It

Several characteristics combine.

Deep, fast root systems. Hemp taproots reach well below the surface layer, accessing contamination that shallow-rooted species miss.

High biomass, quickly. Remediation capacity scales with how much plant material you produce. Hemp produces a great deal in a single season.

Tolerance. Hemp survives and grows in soils where many crops fail, which is exactly the condition remediation sites present.

Low input requirements. Contaminated sites are usually degraded in other ways too. A crop that does not need intensive management is a practical advantage.

Established metal uptake. Hemp has been shown to accumulate cadmium, lead, nickel, zinc and chromium in field studies across multiple countries.

Where It Has Been Applied

Contaminated agricultural land. Fields with elevated cadmium from long-term phosphate fertiliser use, or lead from historical industrial deposition, have been planted with hemp to draw metals down over successive seasons.

Former industrial sites. Brownfield land — old factories, foundries, rail yards, gasworks — typically carries a mix of heavy metals and organic contaminants. Conventional remediation means excavating and disposing of soil, which is expensive and destroys the soil entirely. Hemp offers a slower, far cheaper alternative that leaves the soil in place and improves its structure as it works.

Water treatment. Hemp has been trialled in constructed wetlands and buffer plantings to intercept contaminated water. Root systems take up dissolved metals and support microbial communities that process organic pollutants.

Agricultural runoff. Buffer strips between fields and watercourses intercept excess nitrogen and phosphorus before they reach water, reducing the nutrient loading that drives algal blooms. Hemp’s root density and rapid growth make it a reasonable buffer species.

Radionuclides. The Chernobyl work is real, though frequently overstated. Hemp was among the species trialled for uptake of caesium and strontium. Results were mixed and the approach is slow — it is one tool among several rather than a solution.

The Limits

Phytoremediation is not a fast fix, and honest accounts say so.

It takes multiple growing seasons, sometimes many. It works on the root zone, so deep contamination is out of reach. Uptake efficiency depends heavily on soil chemistry — pH, organic matter and the chemical form of the contaminant all affect whether a metal is available to the plant at all. Some contaminants are not taken up meaningfully by any plant.

And the harvested biomass is itself contaminated waste. It has to be disposed of appropriately, which is a cost and a regulatory question in its own right. Phytoremediation moves contamination from soil into plant material; it does not make it disappear.

The Part That Matters for Testing

Here is the connection that makes this more than an environmental curiosity.

The same uptake mechanism operates whether or not you intend it. A cannabis plant grown for consumption in soil containing lead, arsenic, cadmium or mercury will draw those elements into its tissue. It does not distinguish between a remediation project and a commercial grow.

Contamination reaches a crop through several routes: growing medium with a contaminated history, an untested water source, fertilisers and amendments — cheaper phosphate products in particular can carry cadmium — and atmospheric deposition near industrial sites or major roads.

This is why heavy metal testing is on every compliance panel and why it is not optional. Concentration also increases through processing: extraction concentrates metals along with cannabinoids, so a level that passes in flower can fail in the concentrate made from it. Full detail in contaminant testing explained.

Practical Consequences for Growers

• Know your site history. Land that was industrial, was a rail corridor, sits near a busy road, or has decades of intensive agricultural input carries a higher risk profile. This is worth establishing before planting, not after a failed result.
• Test your soil, not just your product. A baseline soil analysis costs a fraction of a failed batch and tells you what you are working with.
• Test your water. Well water and surface water both carry metals depending on geology and upstream activity.
• Scrutinise inputs. Fertilisers, amendments and growing media are a documented source. Ask suppliers for analysis.
• Do not remediate and crop the same ground. Land undergoing phytoremediation is not land for a consumable crop, for obvious reasons.

Soil and nutrient analysis during cultivation is covered by nutrient monitoring, and the agricultural applications of hemp more broadly in hemp on the farm.

Two Uses, One Property

Hemp’s efficiency as a bioaccumulator is genuinely valuable for cleaning contaminated land, and genuinely dangerous if the same plant is destined for someone’s lungs.

Which is the whole argument for testing. The plant is good at concentrating what is around it, and the only way to know what it concentrated is to measure it.

The post Cannabis as a Phytoremediation Crop appeared first on TruMo Analytics.

What Happened

Charlotte Figi was born in Colorado in 2006. She developed seizures in infancy and was eventually diagnosed with Dravet syndrome — a rare, severe, genetically-driven epilepsy that typically begins in the first year of life and responds poorly to conventional anticonvulsants.

By the time she was five, she was experiencing frequent and prolonged seizures, had lost skills she had previously acquired, and was on a combination of medications with significant side effects and limited benefit. Her family had worked through the standard treatment options.

They turned to a cannabis extract high in CBD and very low in THC — a profile deliberately chosen to avoid intoxication in a young child. The cultivar had been developed by growers in Colorado who had been working on high-CBD plants with little commercial interest at the time, since the market rewarded THC. It was subsequently renamed Charlotte’s Web.

Her family reported a substantial reduction in seizure frequency. The case was covered in a CNN documentary in 2013 by Sanjay Gupta, who used it as part of a public reversal of his own previous position on medical cannabis.

Charlotte died in April 2020, aged 13, following an illness during the early period of the COVID-19 pandemic.

What It Changed

The effect on policy was rapid and specific.

CBD-only laws spread quickly. A number of states that had shown no willingness to pass broad medical cannabis legislation passed narrow laws permitting high-CBD, low-THC preparations, usually for intractable epilepsy. These were limited laws — many were criticised as unworkable, with no legal supply mechanism attached — but they represented the first cannabis legislation in several conservative states.

The public conversation separated CBD from THC. Before this, cannabis was discussed largely as one thing. The case established in the public mind that the plant produces multiple compounds with different properties, and that a non-intoxicating one might have medical use. That distinction underpins the entire CBD market that followed.

Breeding priorities shifted. High-CBD cultivars went from a curiosity to a commercial category. See cannabis strains and the genetics behind them.

Research attention followed. Interest in CBD for epilepsy accelerated, and eventually produced randomised controlled trials supporting a purified CBD formulation for Lennox-Gastaut and Dravet syndromes — now the clearest example of a cannabis-derived medicine meeting the pharmaceutical evidence standard. See the science behind medical cannabis research.

Being Careful About What It Proves

It is worth being precise here, because the case is frequently used to support claims it does not establish.

A single case is not evidence of efficacy. Individual response can reflect the natural course of a condition, concurrent changes in treatment, or expectation effects. That is why controlled trials exist, and it is a general principle rather than skepticism about this case specifically.

What makes the story significant is not that it proved CBD works. It is that it prompted the research that subsequently did establish an effect, for a specific condition, with a specific formulation, at a specific dose. The formal evidence came afterwards.

The distinction matters because the case is routinely invoked to support CBD for conditions where no comparable evidence exists. Approval for two rare severe epilepsy syndromes is a narrow finding, and it does not extend across the retail CBD market.

What It Revealed About Product Consistency

This is the part most relevant to a testing laboratory, and it is usually left out.

The Figi family were administering an unregulated preparation to a child. Its composition depended on the growers producing it. There was no standardized dose, no batch-to-batch verification, and no regulatory framework covering any of it.

Families across the country who moved to Colorado to access similar products faced the same situation — and as demand grew, product quality across the emerging CBD market varied enormously. Independent analyses in the years that followed repeatedly found CBD content well off label claims, undisclosed THC, and contaminants including pesticides and heavy metals.

For a pediatric patient with a severe condition, an inaccurate dose is not a minor problem. If the CBD content of a batch varies by a factor of two, a dose that was working stops working, or produces effects nobody intended.

This is the practical legacy of the case for the testing sector. It made composition verification a mainstream concern rather than a technical one, and it is one of the reasons potency accuracy in cannabis products came to be treated as a safety issue rather than a labeling nicety. See potency testing and why third-party testing matters.

Where It Sits in the Larger Story

Cannabis policy in the United States moved slowly for decades and then quickly, and single cases carried disproportionate weight in that shift — partly because the research that would normally drive policy had been made difficult to conduct by the same laws under debate.

That is a poor way to make policy, and it was the mechanism available. The regulatory history is in from the Marihuana Tax Act to Amendment 3.

What the case ultimately demonstrated is that the question people care about is not whether cannabis has medical potential in the abstract. It is whether a specific product, at a specific composition, does something specific and reliable. Answering that requires measurement — which is the entire premise of cannabis lab testing.

The post Charlotte Figi and the Turning Point for CBD appeared first on TruMo Analytics.